Evidence map›Paper›PMID 42231515›Full record

ArticleCancer imaging : the official publication of the International Cancer Imaging Society2026

[

Lili Lin, Shuye Yang, Wenxin Wang, Xiang Li, Yafei Zhang, Guolin Wang, Xue Wen, Kui Zhao, Jun Yang, Xinhui Su

Abstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer imaging : the official publication of the International Cancer Imaging Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Lili Lin *Department of Nuclear Medicine, The First Affiliated Hospital, Zhejiang University School of Medicine, 79 Qingchun Road, Hangzhou, Zhejiang, 310003, China.
Shuye Yang *Department of Nuclear Medicine, The First Affiliated Hospital, Zhejiang University School of Medicine, 79 Qingchun Road, Hangzhou, Zhejiang, 310003, China.
Wenxin Wang *Department of Nuclear Medicine, The First Affiliated Hospital, Zhejiang University School of Medicine, 79 Qingchun Road, Hangzhou, Zhejiang, 310003, China.
Xiang LiDepartment of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310009, Zhejiang, China.
Yafei ZhangDepartment of Nuclear Medicine, The First Affiliated Hospital, Zhejiang University School of Medicine, 79 Qingchun Road, Hangzhou, Zhejiang, 310003, China.
Guolin WangDepartment of Nuclear Medicine, The First Affiliated Hospital, Zhejiang University School of Medicine, 79 Qingchun Road, Hangzhou, Zhejiang, 310003, China.
Xue WenDepartment of Pathology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310002, Zhejiang, China.
Kui ZhaoDepartment of Nuclear Medicine, The First Affiliated Hospital, Zhejiang University School of Medicine, 79 Qingchun Road, Hangzhou, Zhejiang, 310003, China.
Jun YangDepartment of Nuclear Medicine, The First Affiliated Hospital, Zhejiang University School of Medicine, 79 Qingchun Road, Hangzhou, Zhejiang, 310003, China. yangjun-zy-hz@zju.edu.cn.
Xinhui SuDepartment of Nuclear Medicine, The First Affiliated Hospital, Zhejiang University School of Medicine, 79 Qingchun Road, Hangzhou, Zhejiang, 310003, China. suxinhui@zju.edu.cn.

Funding

2025 National Major Science and Technology Project - New Organizational Model Initiative 2025ZD0552300Jiangxi Provincial Natural Science Foundation 20242BAB23083Major Plan of the Jointly Constructed Project by the Science and Technology Department of the State Administration of Traditional Chinese Medicine and the Zhejiang Provincial Administration of Traditional Chinese Medicine GZY-ZJ-KJ-24025National High-Performance Medical Device Innovation Center Innovation Fund NMED2024CX-01-002National Key Research and Development Program of China 2023YFF0716000National Natural Science Foundation of China 82472013Zhejiang Province Vanguard Plan Project 2025C01111
6 · The paper itself

Abstract

objectivesContrast-enhanced CT (CE-CT) and MRI (CE-MRI) are routine examinations for staging of pancreatic cancer (PC). This study aimed to directly compare the diagnostic performance of the novel [

methodsA total of 127 patients with initial PC who had simultaneously undergone [

resultsFor primary tumor (T) staging, CE-CT and CE-MRI demonstrated equivalent performance and outperformed [

conclusion[

Indexed as

Magnetic Resonance ImagingPancreatic NeoplasmsPositron Emission Tomography Computed TomographyAdultAgedAged, 80 and overContrast MediaFemaleFluorine RadioisotopesHeterocyclic CompoundsHumansMaleMiddle AgedNeoplasm StagingRadiopharmaceuticalsRetrospective StudiesContrast MediaFluorine RadioisotopesHeterocyclic CompoundsRadiopharmaceuticals[18F]AlF-NOTA-FAPI-04 PET/CTClinical stagingContrast-enhanced CTContrast-enhanced MRIPancreatic cancer

Identifiers

PMID42231515
PMCPMC13449600

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.